The Neural Analytics Lucid™ M1 transcranial Doppler Ultrasound System is indicated as an adjunct to the standard clinical practices for measuring and displaying cerebral blood flow velocity within the major conducting arteries and veins of the head and neck. Additionally, the Lucid™ M1 System measures the occurrence of transient emboli signals within the blood stream.
Technology topic
Pharmaceutical Technologies (PT)
The Pharmaceutical Technologies topic covers a wide range of technology areas that advance the discovery, formulation, and manufacture of novel drugs, moieties, compounds, products, processes, platforms or services that will improve the selection, quality or price of pharmaceutical and biologic therapies.
The Pharmaceutical Technologies topic is not aimed at supporting or conducting clinical trials, clinical efficacy and safety studies, the development of pre-clinical or clinical-stage drug candidates, work on medical devices or schedule I substances, or work performed primarily for regulatory purposes. Limited studies with human subjects may be acceptable if they are performed in support of feasibility, proof-of-concept studies of early-stage technologies and must follow NSF policies on research on human subjects. Proposals that request support for clinical studies are noncompliant with the SBIR/STTR solicitations and returned without review.
The NSF SBIR/STTR program no longer supports the development of specific therapeutic molecules. Drug Discovery and Manufacturing are still supported by the program.
Subtopics are not aimed at supporting clinical trials, the clinical validation of information technologies, or medical devices or studies performed primarily for regulatory purposes. Limited studies with human subjects may be acceptable to the extent that they are performed in support of feasibility, such as proof-of-concept studies of early-stage technologies. Proposals that request support for clinical studies will be deemed noncompliant with the SBIR/STTR solicitations and returned without review.
Sub-Topics
PT1. Drug Discovery
PT2. Pharmaceutical and Biologic Manufacturing
PT3. Other Pharmaceutical Technologies
Application process for Pharmaceutical Technologies (PT) funding
Eligibility for Pharmaceutical Technologies (PT) funding +
- Your company must be a small business (fewer than 500 employees) located in the United States.
- At least 50% of your company’s equity must be owned by U.S. citizens or permanent residents. NSF does not fund companies that are majority-owned by multiple venture capital firms, private equity firms, or hedge funds, to participate in SBIR and STTR.
- All funded work, including work done by consultants and contractors, needs to take place in the United States.
- The project’s principal investigator (tech lead) must be legally employed at least 20 hours a week by the company seeking funding. The principal investigator doesn’t need any advanced degrees.
- The principal investigator needs to commit to at least one month (173 hours) of work on a funded project per six months of project duration.
Evaluation Criteria: What We Look for When Evaluating Pharmaceutical Technologies (PT) proposals +
- Technological Innovation
- Broader Impacts
- Commercial Potential
- Read more about our criteria
Take our project assessment to see if your work might be a good fit for NSF funding.
Featured Companies
Detecting biological contaminants in water & pharmaceuticals
Spheryx, Inc. created a technology to monitor, count and characterize microscopic particles in a variety of fluids, such as water, chemicals, or even pharmaceuticals.
To learn more visit: https://spheryx.solutions/
New drug delivery technology for tumor treatment – Tambo
Tambo developed a new technology to activate drugs at specific locations within the body to treat diseases with lower doses of drugs and fewer toxic side effects.
To learn more visit: https://www.shasqi.com/